National Research (NASDAQ:NRC) Stock Passes Above Two Hundred Day Moving Average – Here’s Why

National Research Corporation (NASDAQ:NRC) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $15.84 and traded as high as $18.31. National Research shares last traded at $17.73, with a volume of 135,330 shares trading hands.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered National Research from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, National Research presently has a consensus rating of “Sell”.

National Research Trading Up 1.9%

The stock has a market capitalization of $403.29 million, a P/E ratio of 35.46 and a beta of 0.53. The stock’s 50 day moving average price is $16.84 and its 200-day moving average price is $15.84. The company has a quick ratio of 0.55, a current ratio of 0.55 and a debt-to-equity ratio of 5.36.

National Research (NASDAQ:NRC) last posted its earnings results on Tuesday, February 3rd. The company reported $0.16 earnings per share for the quarter. The company had revenue of $35.19 million during the quarter. National Research had a return on equity of 103.84% and a net margin of 8.44%.

National Research Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 10th. Investors of record on Friday, March 27th will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 3.6%. The ex-dividend date is Friday, March 27th. National Research’s dividend payout ratio is 128.00%.

Institutional Investors Weigh In On National Research

A number of institutional investors have recently added to or reduced their stakes in NRC. Hotchkis & Wiley Capital Management LLC boosted its holdings in shares of National Research by 7.9% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 292,400 shares of the company’s stock valued at $3,737,000 after buying an additional 21,450 shares in the last quarter. AQR Capital Management LLC boosted its stake in National Research by 86.2% in the second quarter. AQR Capital Management LLC now owns 201,396 shares of the company’s stock valued at $3,383,000 after acquiring an additional 93,262 shares in the last quarter. Willis Investment Counsel grew its holdings in National Research by 1.6% in the fourth quarter. Willis Investment Counsel now owns 183,226 shares of the company’s stock worth $3,439,000 after purchasing an additional 2,920 shares during the last quarter. Creative Planning increased its position in shares of National Research by 319.2% during the second quarter. Creative Planning now owns 147,413 shares of the company’s stock worth $2,477,000 after purchasing an additional 112,251 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of National Research by 5.8% during the 2nd quarter. Bank of America Corp DE now owns 122,344 shares of the company’s stock valued at $2,055,000 after purchasing an additional 6,690 shares during the last quarter. Institutional investors own 47.26% of the company’s stock.

About National Research

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.